EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program

Aastha Khanna, Vipin Kumar, Sahil Gola

Indian Journal of Pharmacology · 2026-05 · 58 (3) · 166-175

DOI: 10.4103/ijp.ijp_686_25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Journal of Pharmacology, online erschienen am 01.05.2026. Verfasst von Aastha Khanna und 2 weiteren Autor:innen. Beteiligte Einrichtung: SGT College of Pharmacy, SGT University, Gurugram, Haryana, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Obesity, Anti-Obesity Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity and type 2 diabetes mellitus (T2DM) are widespread health concerns that often coexist, contributing to increased cardiometabolic risks and premature death. Despite advancements in both lifestyle interventions and medical treatments, achieving lasting weight reduction and stable glycemic control remains a major clinical challenge. This review examines findings from the semaglutide treatment effect in people with obesity 1 (STEP) 1–5 trials, which assessed the effectiveness, safety, and long-term outcomes of once-weekly semaglutide 2.4 mg for weight management in adults. These trials included individuals with and without T2DM, enabling comparison across different populations and interventions. In nondiabetic participants (STEP 1, 3, and 4), semaglutide led to average weight reductions between 10% and 17%, while in patients with T2DM (STEP 2), the reduction was around 10%. The inclusion of intensive behavioral therapy in STEP 3 further enhanced weight loss outcomes. Results from STEP 4 highlighted notable weight regain following treatment withdrawal, reflecting the relapsing nature of obesity. STEP 5 confirmed semaglutide’s ability to maintain significant weight loss (~15%) and improve metabolic health over a 2-year period. The most common side effects were gastrointestinal in nature but were generally manageable and nonsevere. Collectively, these trials support semaglutide 2.4 mg as an effective and sustainable option for managing obesity and overweight, including in people with T2DM. The data also emphasize the importance of combining pharmacological therapy with lifestyle modifications and recognize obesity as a long-term condition that necessitates continuous treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesObesityAnti-Obesity AgentsHypoglycemic AgentsHumansSemaglutideWeight LossClinical Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

Glucagon-like peptide-1 antagonistobesitysemaglutidesemaglutide treatment effect in people with obesity trialstype 2 diabetes

Substanzen

SemaglutideGlucagon-Like PeptidesAnti-Obesity AgentsHypoglycemic Agents

Autor:innen und Institutionen

  • SGT College of Pharmacy, SGT University, Gurugram, Haryana, India.
  • Department of Clinical Pharmacology, Aakash Healthcare Super Speciality Hospital, Delhi, India.

Zitieren

APA

Khanna, A., Kumar, V., & Gola, S. (2026). Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program. Indian Journal of Pharmacology, 58(3), 166-175. https://doi.org/10.4103/ijp.ijp_686_25

Vancouver

Khanna A, Kumar V, Gola S. Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program. Indian Journal of Pharmacology. 2026;58(3):166-175. doi:10.4103/ijp.ijp_686_25

BibTeX
@article{Khanna2026,
  author = {Khanna, Aastha and Kumar, Vipin and Gola, Sahil},
  title = {Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program},
  journal = {Indian Journal of Pharmacology},
  year = {2026},
  volume = {58},
  number = {3},
  pages = {166--175},
  doi = {10.4103/ijp.ijp_686_25}
}
Kostenlos starten →